Gilead Sciences
GILD
1,505 hedge funds and large institutions have $81.5B invested in Gilead Sciences in 2017 Q3 according to their latest regulatory filings, with 123 funds opening new positions, 601 increasing their positions, 614 reducing their positions, and 124 closing their positions.
17% more capital invested
Capital invested by funds: $69.4B → $81.5B (+$12.1B)
8% more funds holding in top 10
Funds holding in top 10: 90 → 97 (+7)
2.02% more ownership
Funds ownership: 75% → 77.03% (+2%)
1% less first-time investments, than exits
New positions opened: 123 | Existing positions closed: 124
2% less repeat investments, than reductions
Existing positions increased: 601 | Existing positions reduced: 614
1% less funds holding
Funds holding: 1,521 → 1,505 (-16)
28% less call options, than puts
Call options by funds: $1.89B | Put options by funds: $2.62B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$758M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$398M |
| 3 |
Sanders Capital
West Palm Beach,
Florida
|
+$374M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$357M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$274M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$359M |
| 2 |
D.E. Shaw & Co
New York
|
-$356M |
| 3 |
Barclays
London,
United Kingdom
|
-$246M |
| 4 |
Millennium Management
New York
|
-$208M |
| 5 |
State Street
Boston,
Massachusetts
|
-$207M |
GILD Hedge Fund Activity: Q3 2017 in Review
1,505 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2017, worth a combined $81.5B — up 17% from $69.4B a quarter earlier.
Sellers outnumbered buyers: 124 funds closed out of GILD and 123 opened new positions — a net loss of 1 holder — while 614 trimmed existing stakes and 601 added.
The largest buyer was Dodge & Cox, adding an estimated $758M. The largest seller was Susquehanna International Group, cutting an estimated $359M.
- 1,505 institutional investors held Gilead Sciences (GILD) as of Q3 2017, down from 1,521 in Q2 2017.
- Funds reported $81.5B of Gilead Sciences stock for Q3 2017, up 17% quarter-over-quarter.
- 123 funds opened new Gilead Sciences positions in Q3 2017 and 124 closed out, a net change of -1 holder.
- The largest Gilead Sciences buyer in Q3 2017 was Dodge & Cox, an estimated $758M added.
- The largest Gilead Sciences seller in Q3 2017 was Susquehanna International Group, an estimated $359M sold.
Based on aggregated 13F filings for Q3 2017.